Barclays PLC Akebia Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 273,085 shares of AKBA stock, worth $499,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares

273,085

Previous 273,085 -0.0%

Holding current value

$499,745

Previous $360,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$0.94 - $1.55 $188,453 - $310,747	200,482 Added 276.13%	273,085 $360,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $118,161 - $223,957	-137,397 Reduced 65.43%	72,603 $74,000
Q1 2024 May 15, 2024	BUY	$1.27 - $2.24 $266,700 - $470,400	210,000 New	210,000 $384,000
Q2 2022 Aug 12, 2022	SELL	$0.32 - $0.67 $26,926 - $56,377	-84,146 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.72 - $2.93 $144,449 - $587,828	-200,624 Reduced 70.45%	84,146 $61,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $217,893 - $322,019	96,413 Added 51.19%	284,770 $643,000
Q3 2021 Nov 09, 2021	BUY	$2.35 - $3.88 $44,840 - $74,034	19,081 Added 11.27%	188,357 $542,000
Q2 2021 Aug 13, 2021	SELL	$2.83 - $4.2 $192,275 - $285,356	-67,942 Reduced 28.64%	169,276 $642,000
Q1 2021 May 13, 2021	BUY	$2.92 - $5.06 $214,403 - $371,535	73,426 Added 44.83%	237,218 $804,000
Q4 2020 Feb 11, 2021	SELL	$2.22 - $3.78 $45,956 - $78,249	-20,701 Reduced 11.22%	163,792 $458,000
Q3 2020 Nov 12, 2020	BUY	$2.39 - $13.08 $118,159 - $646,662	49,439 Added 36.61%	184,493 $463,000
Q2 2020 Aug 12, 2020	BUY	$6.67 - $13.58 $8,650 - $17,613	1,297 Added 0.97%	135,054 $1.83 Million
Q1 2020 May 13, 2020	SELL	$4.1 - $10.24 $152,245 - $380,241	-37,133 Reduced 21.73%	133,757 $1.01 Million
Q4 2019 Feb 10, 2020	BUY	$3.16 - $6.73 $164,010 - $349,300	51,902 Added 43.62%	170,890 $1.08 Million
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $37,683 - $57,321	-10,615 Reduced 8.19%	118,988 $467,000
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $85,739 - $168,341	20,912 Added 19.24%	129,603 $628,000
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $576,992 - $931,080	106,653 Added 5233.22%	108,691 $891,000
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $501,307 - $851,014	-93,007 Reduced 97.86%	2,038 $11,000
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $596,985 - $854,556	80,240 Added 541.98%	95,045 $839,000
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $149,511 - $185,295	-16,340 Reduced 52.46%	14,805 $148,000
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $125,424 - $206,364	13,161 Added 73.18%	31,145 $296,000
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $233,763 - $321,589	16,416 Added 1046.94%	17,984 $268,000
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $20,478 - $30,842	1,568	1,568 $30,000

Others Institutions Holding AKBA

# of Institutions

120

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $336M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account